\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Events

Cardiff Oncology Webcast and Conference Call: New Data from KRAS-mutated mCRC Lead Clinical Program
 January 18, 2022
 5:00pm - 5:30pm EST

Cardiff Oncology management will host a webcast and conference call on January 18, 2022 at 5:00 pm ET to present new data from its Phase 1b/2 trial in KRAS-mutated mCRC.  To join the webcast please click on the link provided. To participate by phone, please use the following dial-in information: U.S. Dial-In: 1-877-407-9208; International Dial-In: 1-201-493-6784; Conference ID: 13725845.